One in three infected children dies from this disease
Em um país onde a doença pneumocócica ainda ceifa centenas de vidas infantis por ano, o Brasil dá um passo significativo ao incorporar ao sistema público uma vacina capaz de proteger contra o dobro de cepas bacterianas. A transição da VPC10 para a VPC20 não é apenas uma atualização técnica — é uma resposta a uma realidade que se agravou após a pandemia, com casos de meningite voltando a crescer entre crianças pequenas. A saúde coletiva, como sempre, avança não em linha reta, mas em ciclos de conquista, retrocesso e renovação.
- A doença pneumocócica mata aproximadamente uma em cada três crianças infectadas no Brasil, com 501 mortes registradas apenas em 2024 — uma urgência que não admite demora.
- Após anos de queda nos casos de meningite pneumocócica, a pandemia reverteu o progresso: a média anual subiu de 164 para 211 casos entre 2022 e 2024, pressionando o sistema público a agir.
- Duas cepas específicas — 19A e 3 — respondem por 38% dos casos invasivos e ficavam fora da cobertura da vacina anterior, criando uma lacuna de proteção que a VPC20 agora vem preencher.
- O novo calendário vacinal combina VPC20 e VPC10 em doses escalonadas a partir dos dois meses de vida, com rollout imediato conforme os estados recebem os imunizantes.
- Especialistas alertam: não espere pela nova vacina se a VPC10 estiver disponível — a janela de vulnerabilidade na primeira infância é estreita e cada dose conta.
O Brasil começa a distribuir neste mês uma vacina pneumocócica de nova geração nas unidades públicas de saúde, ampliando a proteção infantil de 10 para 20 cepas do Streptococcus pneumoniae — a bactéria responsável por cerca de metade dos casos de meningite em crianças brasileiras e por uma parcela expressiva das mortes nessa faixa etária.
A mudança responde a um cenário preocupante. Quando a VPC10 foi introduzida, os casos de meningite pneumocócica em crianças menores de cinco anos caíram de uma média de 368 por ano para 164. A pandemia, porém, interrompeu esse avanço: entre 2022 e 2024, a média voltou a subir para 211 casos anuais, com uma taxa de letalidade de cerca de 29%. Em 2024, 501 crianças morreram da doença — 31% de todos os casos registrados no grupo.
Duas cepas em particular — 19A e 3 — concentram 38% dos casos invasivos documentados e não eram cobertas pela vacina anterior. A VPC20, já disponível na rede privada há algum tempo, chega agora ao SUS como uma atualização esperada. O novo esquema prevê doses aos dois meses (VPC20), quatro meses (VPC10) e um reforço aos doze meses (VPC20), com adaptações para crianças que iniciam o calendário mais tarde.
Para quem já completou o esquema com a VPC10 e não tem condições de saúde especiais, não há indicação de dose adicional na rede pública. A transição será gradual, à medida que os estados recebem os imunizantes. A orientação dos especialistas é direta: vacinar com o que estiver disponível, sem aguardar a chegada da nova vacina, pois a proteção precoce é insubstituível.
Brazil's public health system is rolling out a new pneumococcal vaccine this month, one that protects children against twice as many bacterial strains as the shot currently in use. The shift marks a significant expansion of the country's immunization program, driven by rising cases of a disease that kills roughly one in three infected children.
The bacteria in question, Streptococcus pneumoniae, causes everything from ear infections and sinus trouble to pneumonia and meningitis. It accounts for about half of all meningitis cases in Brazilian children and remains a leading cause of death in that age group. For years, the public health system has relied on a 10-valent conjugate vaccine, known as VPC10, which protects against ten variants of the bacterium. Starting this month, states and municipalities will begin receiving doses of a 20-valent version, the VPC20, which covers double the number of strains.
The new vaccine has been available in private clinics for some time, and its addition to the public system represents a long-awaited upgrade. Juarez Cunha, director of the Brazilian Society of Immunizations, notes that two particular strains—19A and 3—have become increasingly problematic. These two account for 38 percent of invasive pneumococcal disease cases documented in Brazil during 2024. The VPC10 did important work in reducing overall pneumococcal illness, but it leaves a gap. More than 1,500 cases of meningitis struck Brazilian children last year from this bacterium alone.
The numbers tell a sobering story. Between 2007 and 2010, before the VPC10 was introduced, meningitis from pneumococcus averaged 368 cases annually in children under five. That dropped to 164 cases per year in the years following the vaccine's rollout between 2013 and 2019. But the pandemic reversed that progress. From 2022 through 2024, cases climbed back to an average of 211 per year. The disease carries a fatality rate of roughly 29 percent overall, and in 2024 alone, 501 children died—accounting for 31 percent of all cases in that age group.
The new vaccination schedule begins at two months of age with the VPC20, followed by a dose of VPC10 at four months, and a booster shot of VPC20 at twelve months. For children starting the series after six months of age, the interval between the first two doses shrinks to thirty days. The booster can be given anytime up to four years and eleven months, though it should come at least sixty days after the previous dose. For children who already completed the full VPC10 series and have no underlying health conditions, public health officials say there is no need for an additional VPC20 dose. Those in the private system, however, may choose to add a supplementary shot.
Cunha emphasizes that parents should not delay vaccination while waiting for the new vaccine to arrive at their local clinic. The VPC10 remains highly effective and the diseases it prevents are serious enough that immediate protection matters. Health posts will begin switching to the VPC20 as soon as their supply arrives, but the transition will unfold gradually across the country's vast network of public clinics. For now, the message is clear: vaccinate with whatever is available, because the window of vulnerability in early childhood is narrow and the stakes are high.
Citas Notables
The strains 19A and 3 represent a significant gap in current protection, and expanding coverage will substantially increase protection for children.— Juarez Cunha, director of the Brazilian Society of Immunizations
Parents should not wait for the new vaccine to arrive—vaccinate immediately with whatever is available, because these are very serious diseases.— Juarez Cunha
La Conversación del Hearth Otra perspectiva de la historia
Why does this vaccine switch matter now, after the VPC10 has been in use for over a decade?
Because two specific strains have become dominant in Brazil—19A and 3—and they account for more than a third of all serious pneumococcal infections. The VPC10 doesn't cover them. Cases were already climbing back up after the pandemic disrupted vaccination rates.
So the old vaccine stopped working?
Not exactly. It still works against the ten strains it targets. But the bacteria evolved, or at least the dominant strains shifted. It's like having a lock that opens ten doors when the problem is now coming through the other twenty.
What happens to kids who already got the VPC10?
In the public system, if they're healthy and completed the series, they don't need anything more. But in private clinics, families can add a VPC20 booster if they want extra coverage. It's a choice available to those who can afford it.
How quickly will this roll out?
Health posts start using it as soon as they receive doses, which is happening now. But Brazil is enormous—getting vaccines to every clinic takes time. The key message is don't wait. If your child needs protection and the VPC10 is available today, use it.
What's the real risk if a child doesn't get vaccinated?
About one in three children who get pneumococcal meningitis dies. Last year, 501 Brazilian children died from this. The vaccine doesn't eliminate risk entirely, but it cuts it dramatically. That's why the timing matters so much in infancy.